Effect of Diuretics Withdrawal in Chronic Heart Failure With Reduced Ejection Fraction (REDICAE)
Heart Failure, Electric Impedance, Dyspnea
About this trial
This is an interventional treatment trial for Heart Failure focused on measuring Heart Failure, Diuretics, Dyspnea, Safety, Fluid overload, Withdraw, Electric Impedance
Eligibility Criteria
INCLUSION CRITERIA: Outpatients diagnosed of chronic HFrEF by criteria of ESC Guidelines of 2021 Age equal or greater than 18 year-old Stable and euvolemic outpatients determined by clinical criteria, biomarkers (CA-125 < 23 U/mL) and bioelectrical impedance analysis Left Ventricular Ejection Fraction less than 50% by echocardiography or cardiovascular magnetic resonance performed within 6 months before the screening visit New York Heart Association functional class I or II No episodes of acute decompensated heart failure within 2 months before the screening visit Treatment with a stable dose of diuretic for at least 1 month before the screening visit Optimal medical therapy with ACEI/ARNI, BB, MRA and iSGLT2 must be started to titration unless any of them were contraindicated or not tolerated Plasma potassium < 5 mg/dl in the screening visit EXCLUSION CRITERIA: Acute coronary syndrome within 3 months before screening visit Awaiting cardiac resynchronization therapy Any severe valve heart disease not yet treated Pulmonary hypertension or any severe pulmonary disease End-stage chronic kidney disease (on hemodialysis). Acute kidney injury Severe hepatic failure or cirrhosis Malignancy on active treatment Congenital heart disease Awaiting cardiac transplantation Inability to understand and sign the informed consent Participation in any other interventional clinical research
Sites / Locations
- Hospital Universitario Reina SofíaRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Diuretics withdrawal
Diuretics maintenance